Treatment Trial

• Mark Orwig participated in a clinical trial for an mRNA vaccine designed to prevent the recurrence of melanoma after surgical tumor removal. • The treatment targets lingering cancer cells that often remain in the body post-surgery, which typically lead to the disease returning. • Scientists believe this personalized mRNA approach could revolutionize cancer care by transforming how doctors treat high-risk patients.

• Moderna and Merck have reported positive results from a large Phase 3 clinical trial of a personalized mRNA-based cancer vaccine designed to treat melanoma. • Unlike traditional treatments, this therapy trains a patient's own immune system to recognize and destroy the specific cancer cells threatening them. • This breakthrough represents a major step forward in precision oncology, moving away from broad attacks on cancer cells toward highly targeted immunotherapy.

• The FDA has approved Pasatru™ (garetosmab-grts) as the first and only treatment to reduce new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with Fibrodysplasia Ossificans Progressiva (FOP). • The approval follows the OPTIMA Phase 3 clinical trial, a multinational study designed to evaluate the drug's efficacy, safety, tolerability, and pharmacokinetics in patients with active FOP. • This development is significant as it provides a targeted therapeutic option for a rare disease, supported by previous Fast Track and Orphan Drug designations from the FDA, EMA, and Japan's Ministry of Health.

• NanoViricides, Inc. (NYSE American: NNVC) announced on August 18, 2026, that it will soon begin a Phase II clinical trial for NV-387 oral gummies. • The trial aims to treat the Bundibugyo Ebola virus during what is described as the largest and most rapidly expanding outbreak to date in the Democratic Republic of Congo. • This development is critical as the company seeks to provide an accessible, antiviral treatment that prevents viral escape during a major public health crisis.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies to treat Ebola in the Democratic Republic of Congo. • The trial aims to combat the current outbreak, which is described as the largest and most expanding in the region's history. • Led by Professor Katoto and supported by experts like Fogarty Fellow Patrick, the study leverages specialized implementation research networks to scale novel treatments.

• NanoViricides, Inc. (NYSE American: NNVC) received regulatory approval on August 10, 2026, to launch a Phase II clinical trial for its NV-387 oral gummies. • The trial will take place in the Democratic Republic of Congo to treat patients affected by the current largest and most rapidly expanding Ebola outbreak. • This development is critical as the company aims to provide an accessible, antiviral treatment designed to prevent viral escape during a public health crisis.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies, designed as a treatment for the Ebola virus. • The trial will take place in the Democratic Republic of Congo to combat the largest and most rapidly expanding Ebola outbreak on record. • The urgency for the treatment is heightened by the virus spreading into displacement camps housing over 4.4 million people, where poor sanitation and medical resources increase risk.

• The first patients have been enrolled in a record-breaking clinical trial for two potential Ebola drugs in the Ituri region of the Democratic Republic of the Congo. • The research program was launched with unprecedented speed, beginning just six weeks after the WHO declared the outbreak a public health emergency on May 17. • This trial is critical because there are currently no approved drugs available to help medical teams treat patients and reduce mortality rates during the outbreak.

Two drugs are being trialled in the Ituri region in a programme set up just six weeks after the outbreak was declared, with hopes it will reduce mortality ratesThere is no approved drug to help the medical teams scrabbling to save lives in the Ebola outbreak in the Democratic Republic of the Congo – but there are hopes that could change within months as the first patients are enrolled in a treatment trial.It is a record pace to set up and start this kind of research, scientists said, with patients enrolled just six weeks after the outbreak being declared a public health emergency of international concern by the World Health Organization (WHO) on 17 May. Continue reading...

• An international clinical trial has launched to evaluate potential treatments for Bundibugyo virus disease (BVD) as patient enrollment begins. • Sponsored by the WHO and coordinated by partners in the DRC, Belgium, and the UK, the study responds to an outbreak in the DRC where over 1,400 people have been diagnosed. • The trial is critical because there are currently no approved therapies for BVD, a disease that has already caused an estimated 440 deaths in the current outbreak.